GBS Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GBS research report →
Price Chart
About the company
Operating across North America and the Asia-Pacific region, GBS Inc. specializes in biosensor diagnostic technology. Its key product is the Saliva Glucose Biosensor, an innovative organic thin-film transistor designed for diabetes management that quantifies glucose levels directly from saliva.
- CEO
- Harry Simeonidis
- IPO
- 2020
- Employees
- 12
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on GBS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $433.58K
- P/E
- -0.23
- PEG
- -0.00
- P/S
- 1.15
- P/B
- 0.64
- EV/EBITDA
- -0.09
- Div Yield
- 0.00%
- Gross Margin
- 32.79%
- Op Margin
- -280.51%
- Net Margin
- -269.31%
- ROE
- -146.09%
- ROIC
- -137.12%
Latest fiscal year · YoY change
- Revenue
- $4.22M+38.1%
- Gross Profit
- $2.05M+64.4%
- Op Income
- $-12,608,085
- Net Income
- $-12,430,975-17.6%
- EPS
- $-8.44-322.0%
- OCF Growth
- -23.2%
- FCF Growth
- -21.6%
- 52W High
- $2.89
- 52W Low
- $0.36
- 50D MA
- $0.47
- 200D MA
- $0.65
- Beta
- 0.00
- RSI (14)
- 48
- Avg Volume
- 51.58K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Intelligent Bio Solutions said the IFP acquisition and new product expansion set up a broader diagnostic platform, while cash runway remains limited into the first half of 2023.· November 9, 2022
- IFP acquisition was the main strategic milestone, expanding IBS into fingerprint-based point-of-care testing and triggering the company name change.
- Management said Australian sales could begin in Q1 2023, while U.S. expansion is viewed as a two-year FDA approval path.
- The company said cash, cash equivalents and marketable securities were approximately $5.74 million at September 30, 2022, down from approximately $8.24 million at June 30, 2022.
- Preliminary net loss for the year ended September 30, 2022 was $1.21 million, or $0.08 per share, improved from a $1.43 million loss, or $0.10 per share, a year earlier.
- Management highlighted grant reimbursements tied to manufacturing milestones and said the next update on clinical studies may come in late Q1 or early Q2 next year.
For the year ended September 30, 2022, the company reported a preliminary net loss of $1.21 million, or $0.08 per share, versus a net loss of $1.43 million, or $0.10 per share, in the prior year. Government support income was $0.31 million in 2022 versus zero in 2021, which management said helped reduce the loss. Cash, cash equivalents and marketable securities were approximately $5.74 million at September 30, 2022, compared with approximately $8.24 million at June 30, 2022. Management said that cash should cover expenses and capital commitments into the first half of 2023, but that forecast does not include revenue from new IFP markets or the potential glucose North American license option.
Harry Simeonidis framed the quarter as a foundational period, centered on completing the IFP acquisition and integrating the two businesses. He emphasized the combined company’s broader technology platform, stronger manufacturing and regulatory capabilities, and the move toward non-invasive diagnostics. His tone was upbeat and expansion-focused, especially around Australia, the U.S., and further international markets.
Spiro Sakiris focused on liquidity, spending, and grant timing. He said cash and marketable securities were approximately $5.74 million at September 30, 2022, down from approximately $8.24 million at June 30, 2022, mainly due to the Newcastle pilot manufacturing facility, lower current liabilities tied to equipment purchases, FX losses, and overhead. He added that grant reimbursements are milestone-based and that the company expects the next stage to come through shortly, while the current runway should last into the first half of 2023.
Analysts asked about the rollout plan for Australia and New Zealand, and management said the immediate focus is regulatory completion, demo units, and back-to-base laboratory testing support, with first sales targeted for Q1 2023. On the U.S. opportunity, management reiterated a two-year FDA path and estimated $2 million to $3 million of funding to access a roughly $3 billion market. Questions also covered the U.K. police force opportunity, the manufacturing grant reimbursement timing, and the cortisol biosensor market; management said interest is significant but the cortisol market is still being evaluated, and clinical study results likely won’t be public until late Q1 or early Q2 next year.
The company now has a more diversified platform after the IFP acquisition, with management saying the combined business has complementary technology, manufacturing, and regulatory capabilities. Management also described strong commercial interest, new client wins, and multiple addressable markets, including Australia, the U.S., Europe, and potential new diagnostic applications beyond drugs of abuse.
The company remains early in commercialization and still faces meaningful execution and regulatory risk, especially for the U.S. where management described a two-year FDA process. Cash was down to approximately $5.74 million at quarter-end, and management said the runway only extends into the first half of 2023 without assuming new revenue or other funding sources. The biosensor program is still in clinical-study preparation, and management has not yet finalized whether some potential tests, like cortisol, are worth pursuing commercially.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 98.1%
- Shares Outstanding
- 916.26K
- Float Shares
- 898.96K
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 22, 22 | Sakiris Spiro Kevin | buy | 47,979 |
| Dec 22, 22 | Sakiris Spiro Kevin | buy | 15,992 |
| Oct 4, 22 | JENKINS DAVID A | other | 0 |
| Oct 4, 22 | JENKINS DAVID A | other | 0 |
| Oct 4, 22 | Isenberg Jason | other | 0 |
| Oct 10, 22 | Simeonidis Harry | other | 80,000 |
| Oct 10, 22 | Hurd Jonathan Scott | other | 15,000 |
| Oct 10, 22 | TOWERS CHRISTOPHER | other | 15,000 |
| Oct 10, 22 | Margelis George | other | 15,000 |
| Oct 10, 22 | FISHER LAWRENCE B | other | 15,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GBS coverage
Recent articles, reports, and earnings notes.
No research on GBS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GBS report →Intuit (INTU) Reports Strong Q4 but Cautious FY27 Guidance Raises Concerns
gurufocus.com · Aug 26
Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia
gurufocus.com · Aug 18
Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation
gurufocus.com · May 27
Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026
gurufocus.com · May 25
Is Intuit (INTU) Undervalued After Q3 FY26 Earnings? EPS $11.09 Beats Estimates, Revenue $8.56B Misses; GF Score 87/100, 51.2% Undervalued
gurufocus.com · May 20
Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA
gurufocus.com · May 19
110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS
globenewswire.com · May 11
Larry Robbins Increases Stake in DXC Technology Co
gurufocus.com · Apr 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.